ALT Altimmune Inc

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune to Participate in Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences:

  • Stifel 2025 Healthcare Conference

    Wednesday, November 12, 2025

    Fireside Chat at 10:00 a.m. ET
  • Jefferies Global Healthcare Conference

    Thursday, November 20, 2025

    Fireside Chat at 9:30 a.m. GMT

The sessions will be webcast and can be accessed by visiting the section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). For more information, please visit .

Follow @Altimmune, Inc. on

Follow @AltimmuneInc on

Investor Contact:

Lee Roth

Burns McClellan

Phone: 646-382-3403

Media Contact:

Elliot Fox

Real Chemistry

This press release was published by a CLEAR® Verified individual.



EN
05/11/2025

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces that Pemvidutide Achieved Key Measures of Success ...

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorable tolerability profile of pemvidutide preserved at 48 weeks, reinforced by low treatment-related discontinuation rate End-of-Phase 2 meeting with FDA supports advancing to registrational Phase 3 trial in MASH patients with moderate to advanced ...

December 19, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces CEO Transition and Succession Plan

Altimmune Announces CEO Transition and Succession Plan Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company’s President and Chief Executive Officer effective January 1, 2026. Altimmune’s Cha...

December 1, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare C...

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows: Conference: Piper Sandler 37th Annual Healthcare ConferenceDate/Time: Wednesday, December 3, 2025 at 2:30 p.m. ET The session will be ...

November 26, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The L...

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in liver fat, inflammation and biomarkers of fibrosis GAITHERSBURG, Md., Nov. 11, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based t...

November 11, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from ...

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and improvements in non-invasive tests vs. placebo at 24 weeks GAITHERSBURG, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-bas...

November 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch